Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

432
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
432
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150
Cancer Survival Analysis01:21

Cancer Survival Analysis

402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Criteria for Causality: Bradford Hill Criteria - II01:28

Criteria for Causality: Bradford Hill Criteria - II

387
The Bradford Hill criteria serve as guidelines for establishing causative links in epidemiological research. Beyond Strength, Consistency, Specificity, and Temporality, key criteria also include Biological Gradient, Plausibility, Coherence, Experiment, and Analogy. These principles assist scientists in assessing the likelihood of causation in complex biological contexts. Below is a summary of these concepts:
387
Hazard Ratio01:12

Hazard Ratio

168
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
168
Actuarial Approach01:20

Actuarial Approach

101
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
101

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating safe doses of perfluorooctane sulfonate (PFOS): an international collaboration.

Archives of toxicology·2025
Same author

Range of the perfluorooctanoate (PFOA) safe dose for human health: An international collaboration.

Regulatory toxicology and pharmacology : RTP·2024
Same author

Analysis for data-derived extrapolation factors for procymidone.

Regulatory toxicology and pharmacology : RTP·2021
Same author

Suggestions for Improving the Characterization of Risk from Exposures to Per and Polyfluorinated Alkyl Substances.

Environmental toxicology and chemistry·2020
Same author

Data derived extrapolation factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA).

Regulatory toxicology and pharmacology : RTP·2019
Same author

Data derived Extrapolation Factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA).

Regulatory toxicology and pharmacology : RTP·2019

Related Experiment Video

Updated: Jul 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Probabilistic methods for non-cancer health effects.

Michael L Dourson1

  • 1Toxicology Excellence for Risk Assessment, 4303 Kirby Avenue, Cincinnati, OH, 45223, USA.

Regulatory Toxicology and Pharmacology : RTP
|June 9, 2023
PubMed
Summary
This summary is machine-generated.

Risk assessment methods for noncancerous health effects have evolved beyond simple safety factors. Harmonizing cancer and non-cancer assessments now considers dose-response relationships and problem formulation with risk managers.

Keywords:
Alliance for risk assessmentHarmonization of cancer and non-cancer methodsNon-cancer health effectsProblem formulationThreshold

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Related Experiment Videos

Last Updated: Jul 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Area of Science:

  • Environmental Health Sciences
  • Toxicology
  • Risk Assessment

Background:

  • Noncancer risk assessment has advanced significantly since the early 1980s.
  • Early methods relied on simple safety factors or linear extrapolation.
  • Harmonization with cancer risk assessment methods has been a key driver of this progress.

Purpose of the Study:

  • To review the advancements in noncancer risk assessment methods.
  • To discuss the harmonization of noncancer and cancer risk assessment approaches.
  • To highlight the importance of problem formulation in risk assessment.

Main Methods:

  • Review of historical risk assessment methodologies.
  • Analysis of case studies from workshops sponsored by the Alliance for Risk Assessment.
  • Examination of recommendations from the National Academy of Sciences (NAS).

Main Results:

  • Dose-response assessment for non-cancer toxicity is more nuanced than previously assumed.
  • Harmonizing cancer and non-cancer methods requires moving beyond simplistic threshold or non-threshold assumptions.
  • Problem formulation with risk managers is crucial before conducting risk assessments.

Conclusions:

  • Modern risk assessment acknowledges the complexity of dose-response relationships for non-cancer effects.
  • Reference Dose (RfD) or virtually safe dose (VSD) estimations are valuable when appropriate.
  • Not all environmental risks necessitate highly precise quantitative solutions.